23 April 2015  
EMA/CHMP/245897/2015 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Esmya 
ulipristal 
On 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Esmya. The marketing authorisation holder for this medicinal product is Gedeon Richter Plc. 
The CHMP adopted a new indication as follows: 
 “Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine 
fibroids in adult women of reproductive age.” 
For information, the full indications for Esmya will be as follows: 
“Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine 
fibroids in adult women of reproductive age. 
Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of 
uterine fibroids in adult women of reproductive age.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
 
  
 
 
 
  
                                                
